OTC Markets OTCPK - Delayed Quote USD

Knight Therapeutics Inc. (KHTRF)

4.4370

0.0000

(0.00%)

At close: May 1 at 4:00:00 PM EDT

Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call

MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 8, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, May 8, 2025 Time: 8:30 a.m. ET Telephone: Toll Free: 1-888-699-1199 or Intern

GlobeNewswire 22 hours ago

KHTRF
0.00%
Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 29, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 5, 2025, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at www.knighttx.com. A

GlobeNewswire 2 days ago

KHTRF
0.00%
TSX Growth Companies With High Insider Ownership April 2025

As the Canadian market navigates a period of cautious optimism, with the TSX only slightly off its record high thanks to strong performance in sectors like materials, investors are keenly observing how trade developments and pro-growth agendas will shape future trends. In this environment, identifying growth companies with high insider ownership can be particularly appealing, as such stocks often signal confidence from those closest to the business and may offer resilience amid market...

Simply Wall St. 3 days ago

AAUCF

WHTCF

KHTRF
0.00%
Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2025 Report on Business magazine’s sixth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. “We are both proud and humble to have Knight Therapeutics Inc. once again featured on the Globe and Mail’s Report on Canada’s Women Le

GlobeNewswire last month

KHTRF
0.00%
TSX Growth Stocks With Up To 86% Insider Driven Earnings Expansion

As the Federal Reserve maintains its interest rates and economic growth shows signs of cooling, Canadian markets are navigating a landscape marked by rising inflation and potential rate cuts from the Bank of Canada. In this environment, stocks with high insider ownership can be appealing as they often signal strong confidence from those closest to the company, potentially aligning well with investor interests in times of economic uncertainty.

Simply Wall St. last month

AOIFF

KHTRF
0.00%

AAUCF
Knight Therapeutics Full Year 2024 Earnings: Beats Expectations

Knight Therapeutics ( TSE:GUD ) Full Year 2024 Results Key Financial Results Revenue: CA$371.3m (up 13% from FY 2023...

Simply Wall St. last month

KHTRF
0.00%
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autolo

GlobeNewswire last month

KHTRF
0.00%

INCY
Knight Therapeutics Inc (KHTRF) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst ...

Knight Therapeutics Inc (KHTRF) reports a 6% revenue increase to over $365 million, while facing a 4% decline in adjusted EBITDA for 2024.

GuruFocus.com last month

KHTRF
0.00%
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

Reports record-high revenues since inceptionMONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial results Revenues were $371,304, an incr

GlobeNewswire last month

KHTRF
0.00%
Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call

MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 financial results on Thursday, March 20, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, March 20, 2025Time: 8:30 a.m. ETTelephone: Toll Free: 1-88

GlobeNewswire last month

KHTRF
0.00%
Knight Therapeutics Price Target Raised at RBC, Raymond James

Analysts at RBC Capital Markets and Raymond James raised their price targets on Knight Therapeutics

PREMIUM
MT Newswires last month

KHTRF
0.00%
Knight Therapeutics to Acquire Paladin

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a definitive Asset Purchase Agreement (“APA”) with Endo Operations Limited (“Endo”) and Paladin Pharma Inc., to acquire the Paladin business (“Paladin”). At closing, Knight will pay an upfront payment of $120 million in cash, including inventory with a value of $20 million. In addition, Knight may pay future

GlobeNewswire last month

KHTRF
0.00%
TSX Growth Companies With High Insider Ownership In February 2025

As we enter February 2025, the Canadian market has seen a modest 3% rise, navigating through stabilized yields and contained inflation rates. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, providing a potential buffer against economic uncertainties.

Simply Wall St. 2 months ago

BDRAF

BDRBF

BDRPF
Knight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®

MONTREAL and LUGANO, Switzerland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced that Knight, through one of its wholly-owned subsidiaries, and Helsinn have expanded their existing

GlobeNewswire 3 months ago

KHTRF
0.00%
3 TSX Growth Stocks Insiders Own With Up To 173% Earnings Growth

As the Canadian market navigates through uncertainties stemming from new U.S. policies on tariffs and energy, the TSX index has shown resilience with gains since Inauguration Day. In this environment, growth companies with high insider ownership can be appealing to investors as they often indicate confidence in the company's future prospects and alignment of interests between insiders and shareholders.

Simply Wall St. 3 months ago

SANG

KHTRF
0.00%

BDIMF
Knight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 41% of the shares, institutions hold 24%

Key Insights The considerable ownership by individual investors in Knight Therapeutics indicates that they collectively...

Simply Wall St. 4 months ago

KHTRF
0.00%
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals,

GlobeNewswire 4 months ago

KHTRF
0.00%

SUPN
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., received regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. "Tr

GlobeNewswire 4 months ago

KHTRF
0.00%
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children. JORNAY PM™ is the first and only evening-dosed methylphenidate product commercially available in Canada to treat ADHD in patients fro

GlobeNewswire 5 months ago

KHTRF
0.00%
Knight Therapeutics (TSE:GUD) investors are sitting on a loss of 33% if they invested five years ago

The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have...

Simply Wall St. 5 months ago

KHTRF
0.00%

Performance Overview

Return	KHTRF	S&P/TSX Composite index (^GSPTSE)
YTD	+22.91%	+0.71%
1-Year	+5.89%	+14.11%
3-Year	+5.82%	+19.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Knight Therapeutics Inc. (KHTRF)

Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call

Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

TSX Growth Companies With High Insider Ownership April 2025

Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity

TSX Growth Stocks With Up To 86% Insider Driven Earnings Expansion

Knight Therapeutics Full Year 2024 Earnings: Beats Expectations

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Knight Therapeutics Inc (KHTRF) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst ...

Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results

Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call

Knight Therapeutics Price Target Raised at RBC, Raymond James

Knight Therapeutics to Acquire Paladin

TSX Growth Companies With High Insider Ownership In February 2025

Knight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®

3 TSX Growth Stocks Insiders Own With Up To 173% Earnings Growth

Knight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 41% of the shares, institutions hold 24%

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Knight Therapeutics (TSE:GUD) investors are sitting on a loss of 33% if they invested five years ago

Performance Overview